Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026401 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
A Phase 2 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02026401 is a Phase 2 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 45 participants.
The verdict
NCT02026401, a Phase 2 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL NGM282
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02026401
The ClinicalTrials.gov registry entry for NCT02026401 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02026401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02026401 about?
NCT02026401 is a clinical study titled "Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis". The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.
What is the current status of trial NCT02026401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02026401?
The interventions under investigation include: Placebo (BIOLOGICAL), NGM282 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02026401?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.